ALIM Alimera Sciences Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 06 January 2020 Alimera Sciences Refinances Its Debt Facility With Solar Capital

   Three-year interest-only periodAdditional $2.5 million available under certain conditions ATLANTA, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization

2. 11 December 2019 Almira Sciences, Inc 13D filing

   CHICAGO, Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ:ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th

3. 04 December 2019 Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

   ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

4. 03 December 2019 Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

   Company continues to execute on its international expansion strategy ATLANTA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of

5. 26 November 2019 Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

   ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

6. 14 November 2019 Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

   ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

7. 13 November 2019 Alimera Sciences Terminates Equity Purchase Agreement

   ATLANTA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

8. 07 November 2019 Alimera Sciences Announces Board's Approval of Reverse Stock Split Ratio

   ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

9. 05 November 2019 Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

   ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of

10. 29 October 2019 Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018International Net Revenue Up 62% Compared to Third Quarter 2018Launch of ILUVIEN® for Non-Infectious Posterior

11. 03 October 2019 Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    ATLANTA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

12. 02 October 2019 Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    ATLANTA, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

13. 01 October 2019 Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

14. 12 September 2019 Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    ATLANTA, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

15. 05 September 2019 Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

16. 03 September 2019 Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal